05:42:30 EDT Tue 22 May 2018
Enter Symbol
or Name

Login ID:

Q:EXEL - Exelixis, Inc. - http://www.exelixis.com05:42:30 EDT
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
EXEL - Q0.120.95 · 21.681.520.93-0.65-3.04,813.0102,79021,81821.63  22.02  20.8232.50  18.03May 21 18:08:54May 1715 min RT 2¢

Recent Trades - Last 10 of 21818
Time ETExPriceChangeVolume

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2018-05-17 01:01U:EXELNews ReleaseExelixis ’ Partner Ipsen Announces European Commission Approval of CABOMETYX ® (Cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma
2018-05-10 01:01U:EXELNews ReleaseExelixis Provides Update on IMblaze370 Phase 3 Pivotal Trial of Atezolizumab and Cobimetinib in Patients With Heavily Pretreated Locally Advanced or Metastatic Colorectal Cancer
2018-05-08 16:05U:EXELNews ReleaseExelixis to Present at the Bank of America Merrill Lynch Health Care Conference on May 15, 2018
2018-05-02 16:06U:EXELNews ReleaseExelixis and Invenra Enter Into Collaboration to Discover and Develop Novel Biologics to Treat Cancer
2018-05-02 16:05U:EXELNews ReleaseExelixis Announces First Quarter 2018 Financial Results and Provides Corporate Update
2018-04-26 08:00U:EXELNews ReleaseCabozantinib to Be Featured in 15 Presentations at ASCO 2018 Annual Meeting